Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine

PHASE4CompletedINTERVENTIONAL
Enrollment

628

Participants

Timeline

Start Date

October 13, 2016

Primary Completion Date

May 19, 2017

Study Completion Date

July 11, 2017

Conditions
Encephalitis, JapaneseMeaslesMumpsRubella
Interventions
BIOLOGICAL

Live attenuated SA 14-14-2 Japanese Encephalitis vaccine

Single 0.5 mL dose of World Health Organization prequalified live, attenuated SA 14-14-2 JE vaccine manufactured by Chengdu Institute of Biological Products, Chengdu, China, administered by subcutaneous injection

BIOLOGICAL

Measles, mumps, rubella vaccine

Single 0.5 mL dose of live, attenuated measles-mumps-rubella vaccine (Schwarz measles virus, RIT 4385 mumps strain, and Wistar RA 27/3 rubella virus) manufactured by GlaxoSmithKline, Inc., administered by subcutaneous injection.

Trial Locations (1)

Unknown

Research Institute for Tropical Medicine, Manila

Sponsors
All Listed Sponsors
collaborator

Research Institute for Tropical Medicine

OTHER_GOV

collaborator

Syneos Health

OTHER

collaborator

DFNet Research Inc.

OTHER

lead

PATH

OTHER